Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL212105 | 0.98 | PNMT (0.58) | PNMTTAAR1DPP4MAOBIDO1 | |
| SCHEMBL14157341 | 0.86 | TAAR1 (0.67) | PNMTTAAR1MAOBCYP1A2GLA | |
| SCHEMBL625763 | 0.82 | PNMT (0.75) | PNMTTAAR1DPP4IDO1LOXL2 | |
| SCHEMBL22469536 | 0.81 | PNMT (0.48) | PNMTTAAR1DPP4LOXL2CYP1A2 | |
| SCHEMBL20560204 | 0.81 | TAAR1 (0.39) | PNMTTAAR1IDO1CYP1A2GLA | |
| SCHEMBL31287302 | 0.81 | PNMT (0.48) | PNMTTAAR1DPP4LOXL2CYP1A2 | |
| SCHEMBL214409 | 0.80 | TAAR1 (0.52) | PNMTTAAR1DPP4MAOBIDO1 | |
| SCHEMBL17552715 | 0.79 | TAAR1 (0.38) | PNMTTAAR1IDO1CYP1A2GLA | |
| SCHEMBL6724455 | 0.79 | TAAR1 (0.41) | PNMTTAAR1IDO1CYP1A2GLA | |
| SCHEMBL5415328 | 0.79 | TAAR1 (0.38) | PNMTTAAR1IDO1CYP1A2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132138-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM (US) | 2026-05-14 | — | — | US | disclosed |
| US-12559497-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4618985-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | Universitat De Barcelona (ES) | 2025-09-24 | — | — | EP | disclosed |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-24 | — | — | US | disclosed |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2024-09-12 | — | — | US | disclosed |
| WO-2024105234-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | UNIVERSITAT DE BARCELONA (ES) | 2024-05-23 | — | — | WO | disclosed |
| EP-4352049-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Avelos Therapeutics Inc. (KR) | 2024-04-17 | — | — | EP | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3609868-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009023193-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023193-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852434-A1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | PNMT 2150/4885TAAR1 4324/4885DPP4 524/4885 |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | PNMT 516/4885TAAR1 3061/4885DPP4 1958/4885 |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | PNMT 108/4885TAAR1 414/4885DPP4 1945/4885 |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | PNMT 2827/4885TAAR1 3621/4885DPP4 2547/4885 |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | PNMT 2827/4885TAAR1 3621/4885DPP4 2547/4885 |
| US-12559497-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, CTCF | PNMT 3340/4885TAAR1 2638/4885DPP4 3592/4885 |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | MAST1, MAST3, MAST4 | PNMT 1574/4885TAAR1 4029/4885DPP4 2134/4885 |
| US-20260132138-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, BRPF3 | PNMT 4139/4885TAAR1 1814/4885DPP4 2453/4885 |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | PNMT 2595/4885TAAR1 2339/4885DPP4 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.